Clinical trial results:
A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Hidradenitis Suppurativa - PIONEER II

Summary

EudraCT number	2011-003406-24
Trial protocol	SE GR DK NL
Global end of trial date	07 July 2014

Results information

Result version number	v1 (current)
This version publication date	20 April 2016
First version publication date	01 August 2015

Trial information

Trial identification

Sponsor protocol code	M11-810

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01468233
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	AbbVie
Sponsor organisation address	1 North Waukegan Road, North Chicago, IL, United States, 60064
Public contact	Global Medical Information, AbbVie, 001 800-633-9110,
Scientific contact	Martin Okun MD, AbbVie, martin.okun@abbvie.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMEA-000366-PIP04-12
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	07 July 2014
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	07 July 2014
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To evaluate the safety and efficacy of treatment with adalimumab in adults with moderate to severe hidradenitis suppurativa (HS).

Protection of trial subjects:

Subject and/or legal guardian read and understood the information provided about the study and gave written permission.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	28 December 2011
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 51
Country: Number of subjects enrolled	Canada: 29
Country: Number of subjects enrolled	Switzerland: 18
Country: Number of subjects enrolled	Turkey: 2
Country: Number of subjects enrolled	United States: 100
Country: Number of subjects enrolled	Netherlands: 17
Country: Number of subjects enrolled	Sweden: 2
Country: Number of subjects enrolled	Denmark: 17
Country: Number of subjects enrolled	France: 45
Country: Number of subjects enrolled	Greece: 45
Worldwide total number of subjects	326
EEA total number of subjects	126

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0

Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	322
From 65 to 84 years	4
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Subjects were enrolled at 53 investigative sites in Australia, Canada, Denmark, Netherlands, Sweden, Switzerland, Turkey, Greece, France and the United States.

Pre-assignment

Screening details:

Subjects ≥ 18 years of age with hidradenitis suppurativa (HS) for at least 1 year prior to Baseline and HS lesions present in at least 2 distinct anatomical areas (one of which must be at least Hurley Stage II or III) who had experienced inadequate response to ≥ 90 day treatment of oral antibiotics for HS were eligible for enrolment in the study.

Period 1

Period 1 title	Treatment Period 1
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Carer, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	Placebo

Arm description:

Placebo for 12 weeks.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Placebo pre-filled syringe, administered by subcutaneous injection

Arm title	Adalimumab Every Week (EW)

Arm description:

Adalimumab ew for 12 weeks (160 mg at Week 0; 80 mg at Week 2; and 40 mg ew from Week 4 to Week 12).

Arm type	Experimental
Investigational medicinal product name	Adalimumab
Investigational medicinal product code	
Other name	Humira
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Adalimumab pre-filled syringe, administered by subcutaneous injection

Number of subjects in period 1	Placebo	Adalimumab Every Week (EW)
Started	163	163
Completed	151	155
Not completed	12	8
Consent withdrawn by subject	3	4
Other, not specified	1	1
Adverse event	5	3
Lost to follow-up	3	-

Period 2

Period 2 title	Treatment Period 2
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Carer, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	Placebo/Placebo

Arm description:

Subjects randomized to receive placebo in Period 1 received placebo every week from Week 12 to Week 35 in Period 2 (up to 24 weeks).

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Placebo pre-filled syringe, administered by subcutaneous injection

Arm title	Adalimumab Every Week (EW)/Placebo

Arm description:

Subjects randomized to receive adalimumab ew in Period 1 were re-randomized to receive placebo ew from Week 12 to Week 35 in Period 2 (up to 24 weeks).

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Placebo pre-filled syringe, administered by subcutaneous injection

Investigational medicinal product name	Adalimumab
Investigational medicinal product code	
Other name	Humira

Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Adalimumab pre-filled syringe, administered by subcutaneous injection

Arm title	Adalimumab Every Week (EW)/ Adalimumab Every Other Week (EOW)

Arm description:

Subjects randomized to receive adalimumab ew in Period 1 were re-randomized to receive 40 mg adalimumab eow from Week 12 to Week 35 in Period 2; placebo injections were administered eow from Week 13 to Week 35 (up to 24 weeks).

Arm type	Experimental
Investigational medicinal product name	Adalimumab
Investigational medicinal product code	
Other name	Humira
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Adalimumab pre-filled syringe, administered by subcutaneous injection

Arm title	Adalimumab Every Week (EW)/Adalimumab Every Week (EW)

Arm description:

Subjects randomized to receive adalimumab ew in Period 1 were re-randomized to receive 40 mg adalimumab ew from Week 12 to Week 35 in Period 2 (up to 24 weeks).

Arm type	Experimental
Investigational medicinal product name	Adalimumab
Investigational medicinal product code	
Other name	Humira
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Adalimumab pre-filled syringe, administered by subcutaneous injection

Number of subjects in period 2	Placebo/Placebo	Adalimumab Every Week (EW)/Placebo	Adalimumab Every Week (EW)/ Adalimumab Every Other Week (EOW)
Started	151	51	53
Completed	40	23	25
Not completed	111	28	28
Consent withdrawn by subject	9	1	1
Other, not specified	3	-	1
Adverse event	3	-	2
Loss or absence of response (per protocol)	84	25	22
Lost to follow-up	3	-	2
Lack of efficacy	9	2	-

Number of subjects in period 2	Adalimumab Every Week (EW)

	/Adalimumab Every Week (EW)
Started	51
Completed	28
Not completed	23
Consent withdrawn by subject	1
Other, not specified	-
Adverse event	1
Loss or absence of response (per protocol)	20
Lost to follow-up	-
Lack of efficacy	1

Baseline characteristics

Reporting groups	
Reporting group title	Placebo
Reporting group description:	
Placebo for 12 weeks.	
Reporting group title	Adalimumab Every Week (EW)
Reporting group description:	
Adalimumab ew for 12 weeks (160 mg at Week 0; 80 mg at Week 2; and 40 mg ew from Week 4 to Week 12).	

Reporting group values	Placebo	Adalimumab Every Week (EW)	Total
Number of subjects	163	163	326
Age categorical Units: Subjects			
Age continuous Units: years			
arithmetic mean	36.1	34.9	
standard deviation	± 12.18	± 9.96	-
Gender categorical Units: Subjects			
Female	113	108	221
Male	50	55	105

End points

End points reporting groups

Reporting group title	Placebo
Reporting group description:	
Placebo for 12 weeks.	
Reporting group title	Adalimumab Every Week (EW)
Reporting group description:	
Adalimumab ew for 12 weeks (160 mg at Week 0; 80 mg at Week 2; and 40 mg ew from Week 4 to Week 12).	
Reporting group title	Placebo/Placebo
Reporting group description:	
Subjects randomized to receive placebo in Period 1 received placebo every week from Week 12 to Week 35 in Period 2 (up to 24 weeks).	
Reporting group title	Adalimumab Every Week (EW)/Placebo
Reporting group description:	
Subjects randomized to receive adalimumab ew in Period 1 were re-randomized to receive placebo ew from Week 12 to Week 35 in Period 2 (up to 24 weeks).	
Reporting group title	Adalimumab Every Week (EW)/ Adalimumab Every Other Week (EOW)
Reporting group description:	
Subjects randomized to receive adalimumab ew in Period 1 were re-randomized to receive 40 mg adalimumab eow from Week 12 to Week 35 in Period 2; placebo injections were administered eow from Week 13 to Week 35 (up to 24 weeks).	
Reporting group title	Adalimumab Every Week (EW)/Adalimumab Every Week (EW)
Reporting group description:	
Subjects randomized to receive adalimumab ew in Period 1 were re-randomized to receive 40 mg adalimumab ew from Week 12 to Week 35 in Period 2 (up to 24 weeks).	
Subject analysis set title	Placebo - Baseline Hurley Stage II
Subject analysis set type	Intention-to-treat
Subject analysis set description:	
Subjects with baseline Hurley Stage II randomized to receive placebo every week (ew) for 12 weeks.	
Subject analysis set title	Placebo - Baseline Hurley Stage III
Subject analysis set type	Intention-to-treat
Subject analysis set description:	
Subjects with baseline Hurley Stage III randomized to receive placebo every week (ew) for 12 weeks.	
Subject analysis set title	Adalimumab Every Week (EW) - Baseline Hurley Stage II
Subject analysis set type	Intention-to-treat
Subject analysis set description:	
Subjects with baseline Hurley Stage II randomized to receive adalimumab ew 160 mg at Week 12, 80 mg at Week 14, and 40 mg ew from Week 16 to 35 (up to 24 weeks).	
Subject analysis set title	Adalimumab Every Week (EW) - Baseline Hurley Stage III
Subject analysis set type	Intention-to-treat
Subject analysis set description:	
Subjects with baseline Hurley Stage III randomized to receive adalimumab ew 160 mg at Week 12, 80 mg at Week 14, and 40 mg ew from Week 16 to 35 (up to 24 weeks).	
Subject analysis set title	Placebo - Baseline NRS at Worst ≥ 3
Subject analysis set type	Intention-to-treat
Subject analysis set description:	
Subjects with baseline Patient's Global Assessment of Skin Pain Numeric Rating Scale (NRS) ≥ 3 randomized to receive placebo every week (ew) for 12 weeks.	
Subject analysis set title	Adalimumab Every Week (EW) - Baseline NRS at Worst ≥ 3
Subject analysis set type	Intention-to-treat

Subject analysis set description:

Subjects with baseline Patient's Global Assessment of Skin Pain Numeric Rating Scale (NRS) ≥ 3 randomized to receive adalimumab ew 160 mg at Week 12, 80 mg at Week 14, and 40 mg ew from Week 16 to 35 (up to 24 weeks).

Primary: Percentage of Subjects Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12

End point title	Percentage of Subjects Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12

End point description:

Hidradenitis Suppurativa Clinical Response (HiSCR) was defined as at least a 50% reduction in abscess and inflammatory nodule (AN) count with no increase in abscess count and no increase in draining fistula count at Week 12 relative to Baseline. Data are presented for all subjects and by baseline Hurley Stage (Stage 1: Abscess formation, single or multiple, without sinus tracts and scarring; Stage II: One or more widely separated recurrent abscesses with tract formation and scars. A subject with at least 1 anatomic region with Hurley Stage II disease and with no anatomic regions with Hurley Stage III disease was classified as Hurley Stage II; and Stage III: Multiple interconnected tracts and abscesses across the entire area, with diffuse or near diffuse involvement. A subject with at least 1 anatomic region with Hurley Stage III disease was classified as Hurley Stage III). Non-responder imputation (NRI): Subjects with missing data were considered non-responders.

End point type	Primary

End point timeframe:

Baseline (Week 0) up to Week 12

End point values	Placebo	Adalimumab Every Week (EW)	Placebo - Baseline Hurley Stage II	Placebo - Baseline Hurley Stage III
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	163	163	87	76
Units: percentage of subjects				
number (not applicable)	27.6	58.9	36.8	17.1

End point values	Adalimumab Every Week (EW) - Baseline Hurley Stage II	Adalimumab Every Week (EW) - Baseline Hurley Stage III		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	85	78		
Units: percentage of subjects				
number (not applicable)	62.4	55.1		

Statistical analyses

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

The p-value was calculated from the Cochran-Mantel-Haenszel test adjusted for baseline Hurley Stage and for baseline antibiotic use.

Comparison groups	Placebo v Adalimumab Every Week (EW)

Number of subjects included in analysis	326
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Cochran-Mantel-Haenszel
Parameter estimate	Adjusted mean difference
Point estimate	31.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	20.7
upper limit	42.2

Statistical analysis title	Statistical Analysis 2
Statistical analysis description:	
The p-value was calculated based on the Cochran-Mantel-Haenszel test adjusted for baseline antibiotic use (Y/N).	
Comparison groups	Placebo - Baseline Hurley Stage II v Adalimumab Every Week (EW) - Baseline Hurley Stage II
Number of subjects included in analysis	172
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Cochran-Mantel-Haenszel
Parameter estimate	Adjusted mean difference
Point estimate	25.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	10.5
upper limit	40.5

Statistical analysis title	Statistical Analysis 3
Statistical analysis description:	
The p-value was calculated based on the Cochran-Mantel-Haenszel test adjusted for baseline antibiotic use (Y/N).	
Comparison groups	Placebo - Baseline Hurley Stage III v Adalimumab Every Week (EW) - Baseline Hurley Stage III
Number of subjects included in analysis	154
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Cochran-Mantel-Haenszel
Parameter estimate	Adjusted mean difference
Point estimate	38.1

Confidence interval	
level	95 %
sides	2-sided
lower limit	22.8
upper limit	53.3

Secondary: Percentage of Subjects with Baseline Hurley Stage II who Achieved Abscess and Inflammatory Nodule (AN) Count of 0, 1, or 2 at Week 12

End point title	Percentage of Subjects with Baseline Hurley Stage II who Achieved Abscess and Inflammatory Nodule (AN) Count of 0, 1, or 2 at Week 12

End point description:

The percentage of subjects with AN counts lowered to 0, 1, or 2 at Week 12 among subjects with Hurley Stage II at Baseline. Non-responder imputation (NRI): Subjects with missing data were considered nonresponders.

End point type	Secondary

End point timeframe:

Baseline (Week 0) up to Week 12

End point values	Placebo - Baseline Hurley Stage II	Adalimumab Every Week (EW) - Baseline Hurley Stage II		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	87	85		
Units: percentage of subjects				
number (not applicable)	32.2	51.8		

Statistical analyses

Statistical analysis title	Statistical analysis 1

Statistical analysis description:

Secondary end points 1 (AN 0/1/2 counts), 2 (NRS30), and 3 (modified Sartorius score) were ranked analyses. The p-value for the AN 0/1/2 counts end point was calculated from the Cochran-Mantel-Haenszel test adjusted for baseline antibiotics use (Y/N).

Comparison groups	Placebo - Baseline Hurley Stage II v Adalimumab Every Week (EW) - Baseline Hurley Stage II
Number of subjects included in analysis	172
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.01
Method	Cochran-Mantel-Haenszel
Parameter estimate	Adjusted mean difference
Point estimate	19.5

Confidence interval	
level	95 %
sides	2-sided
lower limit	4.7
upper limit	34.2

Secondary: Percentage of Subjects Achieving At Least 30% Reduction and At Least 1 Unit Reduction from Baseline in Patient's Global Assessment of Skin Pain (NRS30) – At Worst at Week 12 Among Subjects with Baseline Skin Pain NRS ≥ 3

End point title	Percentage of Subjects Achieving At Least 30% Reduction and At Least 1 Unit Reduction from Baseline in Patient's Global Assessment of Skin Pain (NRS30) – At Worst at Week 12 Among Subjects with Baseline Skin Pain NRS ≥ 3

End point description:

The Patient's Global Assessment of Skin Pain Numeric Rating Scale (NRS) was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by subjects before they went to bed and responded to the items based on a recall period of the "last 24 hours." The percentage of subjects who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the Patient's Global Assessment of Skin Pain (NRS30) – at worst at Week 12 among subjects with Baseline NRS ≥ 3 is presented. Weekly averages of daily assessments were analyzed. Non-responder imputation (NRI): Subjects with missing data were considered non-responders.

End point type	Secondary

End point timeframe:

Baseline (Week 0) up to Week 12

End point values	Placebo - Baseline NRS at Worst ≥ 3	Adalimumab Every Week (EW) - Baseline NRS at Worst ≥ 3		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	111	105		
Units: percentage of subjects				
number (not applicable)	20.7	45.7		

Statistical analyses

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

Secondary end points 1 (AN 0/1/2 counts), 2 (NRS30), and 3 (modified Sartorius score) were ranked analyses. The p-value for the NRS30 end point was calculated from the Cochran-Mantel-Haenszel test adjusted for baseline Hurley Stage and antibiotics use (Y/N).

Comparison groups	Placebo - Baseline NRS at Worst ≥ 3 v Adalimumab Every Week (EW) - Baseline NRS at Worst ≥ 3

Number of subjects included in analysis	216
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	Cochran-Mantel-Haenszel
Parameter estimate	Adjusted mean difference
Point estimate	25.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	12.7
upper limit	37.6

Secondary: Change from Baseline to Week 12 in Modified Sartorius Score

End point title	Change from Baseline to Week 12 in Modified Sartorius Score

End point description:

The Sartorius Scale is used to quantify the severity of HS. Points are awarded for 12 body areas (left and right axillae, left and right sub/inframammary areas, intermammary area, left and right buttocks, left and right inguino-crural folds, perianal area, perineal area, and other): points were awarded for nodules (2 points for each); abscesses (4 points); fistulas (4 points); scars (1 point); other findings (1 point); and longest distance between two lesions (2-6 points, 0 if no lesions); and if lesions are separated by normal skin (yes-0 points; No-6 points). The total Sartorius score is the sum of the 12 regional scores. Last Observation Carried Forward (LOCF): The last completed evaluation from the previous visit within the particular period for efficacy measures was carried forward to impute missing data at later visits in the same period. Baseline efficacy evaluations were not carried forward.

End point type	Secondary

End point timeframe:

Baseline (Week 0) and Week 12

End point values	Placebo	Adalimumab Every Week (EW)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	162	163		
Units: units on a scale				
least squares mean (standard error)	-9.5 (± 3.84)	-28.9 (± 3.85)		

Statistical analyses

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

Secondary end points 1 (AN 0/1/2 counts), 2 (NRS30), and 3 (modified Sartorius score) were ranked analyses. The p-value for the modified Sartorius score end point was calculated from ANCOVA with stratum (baseline Hurley Stage and antibiotics use), baseline value, and treatment as covariates.

Comparison groups	Placebo v Adalimumab Every Week (EW)

Number of subjects included in analysis	325
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.001
Method	ANCOVA
Parameter estimate	LS mean difference
Point estimate	-19.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-28.6
upper limit	-10.1

Adverse events

Adverse events information

Timeframe for reporting adverse events:

AEs were collected from first dose of study drug until 70 days following last dose of study drug (46 weeks); SAEs were collected from the time that informed consent was obtained (up to 50 weeks).

Adverse event reporting additional description:

AEs with onset in Period 1 were collected from first dose of study drug until prior to the first dose in Period 2, or up to 70 days following last dose of study drug if the subject discontinued during Period 1.

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	16.1

Reporting groups

Reporting group title	Placebo (Period 1)

Reporting group description:

Placebo for 12 weeks

Reporting group title	Adalimumab EW (Period 1)

Reporting group description:

Adalimumab ew for 12 weeks (160 mg at Week 0; 80 mg at Week 2; and 40 mg ew from Week 4 to Week 12).

Reporting group title	Placebo/Placebo (Period 2)

Reporting group description:

Subjects randomized to receive placebo in Period 1 received placebo ew from Week 12 to Week 35 in Period 2 (up to 24 weeks).

Reporting group title	Adalimumab EW/Placebo (Period 2)

Reporting group description:

Subjects randomized to receive adalimumab ew in Period 1 were re-randomized to receive placebo ew from Week 12 to Week 35 in Period 2 (up to 24 weeks).

Reporting group title	Adalimumab EW/Adalimumab EOW (Period 2)

Reporting group description:

Subjects randomized to receive adalimumab ew in Period 1 were re-randomized to receive 40 mg adalimumab eow from Week 12 to Week 35 in Period 2; placebo injections were administered eow from Week 13 to Week 35 (up to 24 weeks).

Reporting group title	Adalimumab EW/Adalimumab EW (Period 2)

Reporting group description:

Subjects randomized to receive adalimumab ew in Period 1 were re-randomized to receive 40 mg adalimumab ew from Week 12 to Week 35 in Period 2 (up to 24 weeks).

Serious adverse events	Placebo (Period 1)	Adalimumab EW (Period 1)	Placebo/Placebo (Period 2)
Total subjects affected by serious adverse events			
subjects affected / exposed	6 / 163 (3.68%)	3 / 163 (1.84%)	7 / 151 (4.64%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Vascular disorders			
Intra-abdominal haematoma			

subjects affected / exposed	0 / 163 (0.00%)	0 / 163 (0.00%)	1 / 151 (0.66%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
Abortion induced			
subjects affected / exposed	0 / 163 (0.00%)	0 / 163 (0.00%)	1 / 151 (0.66%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	1 / 163 (0.61%)	0 / 163 (0.00%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Social circumstances			
Sexual abuse			
subjects affected / exposed	0 / 163 (0.00%)	1 / 163 (0.61%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Suicide attempt			
subjects affected / exposed	1 / 163 (0.61%)	0 / 163 (0.00%)	1 / 151 (0.66%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Depression			
subjects affected / exposed	0 / 163 (0.00%)	0 / 163 (0.00%)	1 / 151 (0.66%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
International normalised ratio increased			
subjects affected / exposed	1 / 163 (0.61%)	0 / 163 (0.00%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			

Accidental overdose			
subjects affected / exposed	1 / 163 (0.61%)	0 / 163 (0.00%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tendon rupture			
subjects affected / exposed	0 / 163 (0.00%)	1 / 163 (0.61%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute myocardial infarction			
subjects affected / exposed	0 / 163 (0.00%)	0 / 163 (0.00%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardio-respiratory arrest			
subjects affected / exposed	0 / 163 (0.00%)	0 / 163 (0.00%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	0 / 163 (0.00%)	0 / 163 (0.00%)	1 / 151 (0.66%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Dizziness			
subjects affected / exposed	1 / 163 (0.61%)	0 / 163 (0.00%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Presyncope			
subjects affected / exposed	1 / 163 (0.61%)	0 / 163 (0.00%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			

subjects affected / exposed	1 / 163 (0.61%)	0 / 163 (0.00%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphadenitis			
subjects affected / exposed	0 / 163 (0.00%)	0 / 163 (0.00%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Hidradenitis			
subjects affected / exposed	2 / 163 (1.23%)	0 / 163 (0.00%)	1 / 151 (0.66%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash			
subjects affected / exposed	0 / 163 (0.00%)	0 / 163 (0.00%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Renal failure acute			
subjects affected / exposed	0 / 163 (0.00%)	1 / 163 (0.61%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal colic			
subjects affected / exposed	0 / 163 (0.00%)	0 / 163 (0.00%)	1 / 151 (0.66%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Gastroenteritis			
subjects affected / exposed	1 / 163 (0.61%)	0 / 163 (0.00%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection			
subjects affected / exposed	0 / 163 (0.00%)	1 / 163 (0.61%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Viral infection			
subjects affected / exposed	1 / 163 (0.61%)	0 / 163 (0.00%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
subjects affected / exposed	0 / 163 (0.00%)	0 / 163 (0.00%)	1 / 151 (0.66%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile infection			
subjects affected / exposed	0 / 163 (0.00%)	0 / 163 (0.00%)	1 / 151 (0.66%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 163 (0.00%)	0 / 163 (0.00%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Diabetes mellitus inadequate control			
subjects affected / exposed	1 / 163 (0.61%)	0 / 163 (0.00%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Adalimumab EW/Placebo (Period 2)	Adalimumab EW/Adalimumab EOW (Period 2)	Adalimumab EW/Adalimumab EW (Period 2)
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 51 (0.00%)	2 / 53 (3.77%)	2 / 51 (3.92%)
number of deaths (all causes)	0	1	0
number of deaths resulting from adverse events			
Vascular disorders			
Intra-abdominal haematoma			
subjects affected / exposed	0 / 51 (0.00%)	0 / 53 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
Abortion induced			

subjects affected / exposed	0 / 51 (0.00%)	0 / 53 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	0 / 51 (0.00%)	0 / 53 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Social circumstances			
Sexual abuse			
subjects affected / exposed	0 / 51 (0.00%)	0 / 53 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Suicide attempt			
subjects affected / exposed	0 / 51 (0.00%)	0 / 53 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Depression			
subjects affected / exposed	0 / 51 (0.00%)	0 / 53 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
International normalised ratio increased			
subjects affected / exposed	0 / 51 (0.00%)	0 / 53 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Accidental overdose			
subjects affected / exposed	0 / 51 (0.00%)	0 / 53 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tendon rupture			

subjects affected / exposed	0 / 51 (0.00%)	0 / 53 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute myocardial infarction			
subjects affected / exposed	0 / 51 (0.00%)	1 / 53 (1.89%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardio-respiratory arrest			
subjects affected / exposed	0 / 51 (0.00%)	1 / 53 (1.89%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Atrial fibrillation			
subjects affected / exposed	0 / 51 (0.00%)	0 / 53 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 51 (0.00%)	0 / 53 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Presyncope			
subjects affected / exposed	0 / 51 (0.00%)	0 / 53 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 51 (0.00%)	0 / 53 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphadenitis			
subjects affected / exposed	0 / 51 (0.00%)	1 / 53 (1.89%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Skin and subcutaneous tissue disorders			
Hidradenitis			
subjects affected / exposed	0 / 51 (0.00%)	1 / 53 (1.89%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash			
subjects affected / exposed	0 / 51 (0.00%)	0 / 53 (0.00%)	1 / 51 (1.96%)
occurrences causally related to treatment / all	0 / 0	0 / 0	3 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Renal failure acute			
subjects affected / exposed	0 / 51 (0.00%)	0 / 53 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal colic			
subjects affected / exposed	0 / 51 (0.00%)	0 / 53 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Gastroenteritis			
subjects affected / exposed	0 / 51 (0.00%)	0 / 53 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection			
subjects affected / exposed	0 / 51 (0.00%)	0 / 53 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			
subjects affected / exposed	0 / 51 (0.00%)	0 / 53 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			

subjects affected / exposed	0 / 51 (0.00%)	0 / 53 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile infection			
subjects affected / exposed	0 / 51 (0.00%)	0 / 53 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 51 (0.00%)	0 / 53 (0.00%)	1 / 51 (1.96%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Diabetes mellitus inadequate control			
subjects affected / exposed	0 / 51 (0.00%)	0 / 53 (0.00%)	0 / 51 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 2 %

Non-serious adverse events	Placebo (Period 1)	Adalimumab EW (Period 1)	Placebo/Placebo (Period 2)
Total subjects affected by non-serious adverse events			
subjects affected / exposed	77 / 163 (47.24%)	66 / 163 (40.49%)	48 / 151 (31.79%)
Nervous system disorders			
Dizziness			
subjects affected / exposed	1 / 163 (0.61%)	7 / 163 (4.29%)	1 / 151 (0.66%)
occurrences (all)	1	10	1
Headache			
subjects affected / exposed	21 / 163 (12.88%)	21 / 163 (12.88%)	4 / 151 (2.65%)
occurrences (all)	29	30	5
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	6 / 163 (3.68%)	0 / 163 (0.00%)	2 / 151 (1.32%)
occurrences (all)	7	0	2
Fatigue			

subjects affected / exposed	2 / 163 (1.23%)	5 / 163 (3.07%)	0 / 151 (0.00%)
occurrences (all)	2	6	0
Injection site pain			
subjects affected / exposed	5 / 163 (3.07%)	6 / 163 (3.68%)	0 / 151 (0.00%)
occurrences (all)	6	6	0
Pyrexia			
subjects affected / exposed	2 / 163 (1.23%)	1 / 163 (0.61%)	2 / 151 (1.32%)
occurrences (all)	2	1	3
Eye disorders			
Conjunctivitis			
subjects affected / exposed	1 / 163 (0.61%)	0 / 163 (0.00%)	2 / 151 (1.32%)
occurrences (all)	1	0	3
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	4 / 163 (2.45%)	9 / 163 (5.52%)	2 / 151 (1.32%)
occurrences (all)	4	9	2
Nausea			
subjects affected / exposed	5 / 163 (3.07%)	7 / 163 (4.29%)	0 / 151 (0.00%)
occurrences (all)	6	7	0
Toothache			
subjects affected / exposed	1 / 163 (0.61%)	2 / 163 (1.23%)	3 / 151 (1.99%)
occurrences (all)	1	2	3
Vomiting			
subjects affected / exposed	2 / 163 (1.23%)	4 / 163 (2.45%)	0 / 151 (0.00%)
occurrences (all)	2	4	0
Skin and subcutaneous tissue disorders			
Hidradenitis			
subjects affected / exposed	19 / 163 (11.66%)	7 / 163 (4.29%)	13 / 151 (8.61%)
occurrences (all)	21	8	15
Dermatitis contact			
subjects affected / exposed	2 / 163 (1.23%)	0 / 163 (0.00%)	3 / 151 (1.99%)
occurrences (all)	2	0	3
Erythema			
subjects affected / exposed	0 / 163 (0.00%)	1 / 163 (0.61%)	0 / 151 (0.00%)
occurrences (all)	0	1	0
Psychiatric disorders			

Insomnia			
subjects affected / exposed	4 / 163 (2.45%)	1 / 163 (0.61%)	2 / 151 (1.32%)
occurrences (all)	4	1	2
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	3 / 163 (1.84%)	3 / 163 (1.84%)	4 / 151 (2.65%)
occurrences (all)	3	3	4
Muscle spasms			
subjects affected / exposed	1 / 163 (0.61%)	2 / 163 (1.23%)	1 / 151 (0.66%)
occurrences (all)	1	2	1
Infections and infestations			
Folliculitis			
subjects affected / exposed	0 / 163 (0.00%)	4 / 163 (2.45%)	0 / 151 (0.00%)
occurrences (all)	0	4	0
Gastroenteritis			
subjects affected / exposed	3 / 163 (1.84%)	5 / 163 (3.07%)	7 / 151 (4.64%)
occurrences (all)	3	6	7
Gastroenteritis viral			
subjects affected / exposed	1 / 163 (0.61%)	0 / 163 (0.00%)	0 / 151 (0.00%)
occurrences (all)	1	0	0
Influenza			
subjects affected / exposed	3 / 163 (1.84%)	3 / 163 (1.84%)	3 / 151 (1.99%)
occurrences (all)	3	3	3
Upper respiratory tract infection			
subjects affected / exposed	9 / 163 (5.52%)	8 / 163 (4.91%)	13 / 151 (8.61%)
occurrences (all)	9	9	17
Urinary tract infection			
subjects affected / exposed	5 / 163 (3.07%)	1 / 163 (0.61%)	3 / 151 (1.99%)
occurrences (all)	5	1	3
Bronchitis			
subjects affected / exposed	4 / 163 (2.45%)	2 / 163 (1.23%)	2 / 151 (1.32%)
occurrences (all)	5	2	2
Nasopharyngitis			
subjects affected / exposed	10 / 163 (6.13%)	9 / 163 (5.52%)	5 / 151 (3.31%)
occurrences (all)	11	11	6
Pharyngitis			

subjects affected / exposed	0 / 163 (0.00%)	3 / 163 (1.84%)	0 / 151 (0.00%)
occurrences (all)	0	3	0
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 163 (0.00%)	0 / 163 (0.00%)	0 / 151 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Diabetes mellitus			
subjects affected / exposed	0 / 163 (0.00%)	0 / 163 (0.00%)	0 / 151 (0.00%)
occurrences (all)	0	0	0
Vitamin D deficiency			
subjects affected / exposed	0 / 163 (0.00%)	0 / 163 (0.00%)	0 / 151 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Adalimumab EW/Placebo (Period 2)	Adalimumab EW/Adalimumab EOW (Period 2)	Adalimumab EW/Adalimumab EW (Period 2)
Total subjects affected by non-serious adverse events			
subjects affected / exposed	27 / 51 (52.94%)	25 / 53 (47.17%)	21 / 51 (41.18%)
Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 51 (0.00%)	0 / 53 (0.00%)	0 / 51 (0.00%)
occurrences (all)	0	0	0
Headache			
subjects affected / exposed	4 / 51 (7.84%)	3 / 53 (5.66%)	5 / 51 (9.80%)
occurrences (all)	4	5	5
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	1 / 51 (1.96%)	0 / 53 (0.00%)	0 / 51 (0.00%)
occurrences (all)	1	0	0
Fatigue			
subjects affected / exposed	1 / 51 (1.96%)	0 / 53 (0.00%)	1 / 51 (1.96%)
occurrences (all)	1	0	1
Injection site pain			
subjects affected / exposed	0 / 51 (0.00%)	0 / 53 (0.00%)	0 / 51 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	1 / 51 (1.96%)	2 / 53 (3.77%)	1 / 51 (1.96%)
occurrences (all)	1	2	1

Eye disorders			
Conjunctivitis			
subjects affected / exposed	2 / 51 (3.92%)	1 / 53 (1.89%)	1 / 51 (1.96%)
occurrences (all)	2	1	2
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	1 / 51 (1.96%)	4 / 53 (7.55%)	1 / 51 (1.96%)
occurrences (all)	1	4	1
Nausea			
subjects affected / exposed	1 / 51 (1.96%)	1 / 53 (1.89%)	1 / 51 (1.96%)
occurrences (all)	1	1	1
Toothache			
subjects affected / exposed	3 / 51 (5.88%)	0 / 53 (0.00%)	1 / 51 (1.96%)
occurrences (all)	3	0	1
Vomiting			
subjects affected / exposed	0 / 51 (0.00%)	2 / 53 (3.77%)	0 / 51 (0.00%)
occurrences (all)	0	2	0
Skin and subcutaneous tissue disorders			
Hidradenitis			
subjects affected / exposed	10 / 51 (19.61%)	8 / 53 (15.09%)	3 / 51 (5.88%)
occurrences (all)	12	9	4
Dermatitis contact			
subjects affected / exposed	2 / 51 (3.92%)	0 / 53 (0.00%)	0 / 51 (0.00%)
occurrences (all)	2	0	0
Erythema			
subjects affected / exposed	0 / 51 (0.00%)	2 / 53 (3.77%)	0 / 51 (0.00%)
occurrences (all)	0	2	0
Psychiatric disorders			
Insomnia			
subjects affected / exposed	0 / 51 (0.00%)	0 / 53 (0.00%)	0 / 51 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 51 (0.00%)	1 / 53 (1.89%)	2 / 51 (3.92%)
occurrences (all)	0	1	2
Muscle spasms			

subjects affected / exposed	2 / 51 (3.92%)	0 / 53 (0.00%)	0 / 51 (0.00%)
occurrences (all)	2	0	0
Infections and infestations			
Folliculitis			
subjects affected / exposed	1 / 51 (1.96%)	0 / 53 (0.00%)	2 / 51 (3.92%)
occurrences (all)	1	0	2
Gastroenteritis			
subjects affected / exposed	1 / 51 (1.96%)	2 / 53 (3.77%)	1 / 51 (1.96%)
occurrences (all)	1	3	1
Gastroenteritis viral			
subjects affected / exposed	0 / 51 (0.00%)	2 / 53 (3.77%)	3 / 51 (5.88%)
occurrences (all)	0	2	3
Influenza			
subjects affected / exposed	2 / 51 (3.92%)	0 / 53 (0.00%)	3 / 51 (5.88%)
occurrences (all)	3	0	3
Upper respiratory tract infection			
subjects affected / exposed	5 / 51 (9.80%)	4 / 53 (7.55%)	1 / 51 (1.96%)
occurrences (all)	7	4	1
Urinary tract infection			
subjects affected / exposed	1 / 51 (1.96%)	1 / 53 (1.89%)	0 / 51 (0.00%)
occurrences (all)	1	1	0
Bronchitis			
subjects affected / exposed	3 / 51 (5.88%)	0 / 53 (0.00%)	1 / 51 (1.96%)
occurrences (all)	6	0	1
Nasopharyngitis			
subjects affected / exposed	1 / 51 (1.96%)	3 / 53 (5.66%)	3 / 51 (5.88%)
occurrences (all)	1	6	4
Pharyngitis			
subjects affected / exposed	0 / 51 (0.00%)	2 / 53 (3.77%)	0 / 51 (0.00%)
occurrences (all)	0	2	0
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 51 (0.00%)	0 / 53 (0.00%)	2 / 51 (3.92%)
occurrences (all)	0	0	2
Metabolism and nutrition disorders			
Diabetes mellitus			

subjects affected / exposed	0 / 51 (0.00%)	2 / 53 (3.77%)	1 / 51 (1.96%)
occurrences (all)	0	2	1
Vitamin D deficiency			
subjects affected / exposed	1 / 51 (1.96%)	2 / 53 (3.77%)	0 / 51 (0.00%)
occurrences (all)	1	2	0

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
13 February 2012	Clarified TB testing at screening; revised anti-TB therapy to a minimum of 4 weeks completed prior to starting TNF inhibitors; provided a process of HIV antibody testing where required by country regulatory authorities; for the analysis of proportion of subjects achieving at least 30% reduction at least 1 unity reduction from baseline NRS30 - at worst at Week 12, increase baseline requirement from baseline NRS ≥1 to ≥3; classified methods of handling potential confounding effect on pain assessment when medications for HS or pain were used.
12 April 2012	Added lesion count assessments at unscheduled visits after Week 12; added waist circumference measurements to assessments; added collection of NRS pain and analgesic use using an electronic device; added representative lesion assessments at premature discontinuation visit if the visit occurred prior to Week 12.
07 August 2013	Added safety monitoring language per AbbVie participation in US FDA-requested TNF inhibitor class wide exploration of the rare appearance of malignancy in patients 30 years of age or younger; provided more details to the risks and benefits of participation; added recently approved biologic therapies as prohibited therapies; added blood samples for biologic marker analysis at Week 36 (or premature discontinuation); added change and percent change from baseline in CRP; replaced pregnancy forms and the pregnancy registry with EDC system entry for pregnancy determination.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported